New drugs on the horizon: matrix metalloproteinase inhibitors.
Rothenberg
M L
ML
Vanderbilt University Medical Center, Department of Medicine and the Nashville Veterans Affairs Medical Center, Tennessee 37232-5536, USA.
Nelson
A R
AR
Hande
K R
KR
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001381:Azepines / Q000494:pharmacology; D001713:Biphenyl Compounds; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D009930:Organic Chemicals; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology; D010654:Phenylbutyrates; D011480:Protease Inhibitors / Q000494:pharmacology*; D011719:Pyrazines; D013449:Sulfonamides; D013876:Thiophenes / Q000494:pharmacology
D000970:Antineoplastic Agents; D001381:Azepines; D001713:Biphenyl Compounds; C097658:CGS 27023A; D006877:Hydroxamic Acids; D009930:Organic Chemicals; D010654:Phenylbutyrates; D011480:Protease Inhibitors; D011719:Pyrazines; D013449:Sulfonamides; D013876:Thiophenes; C113282:prinomastat; D010649:Phenylalanine; C113281:Bay 12-9566; C080985:batimastat; C100342:marimastat; D008666:Metalloendopeptidases